OncoSil Medical (ASX:OSL) achieved 50% of its target recruits for its TRIPP-FFX clinical trial, with the 40th patient randomized, according to a Thursday filing with the Australian bourse.
The trial aims to assess the safety and efficacy of OncoSil when given in addition to standard Folfirinox chemotherapy in treating locally advanced pancreatic cancer, the filing stated.
Meanwhile, the company reached the halfway point of patient recruitment in its Pancosil clinical trial, with the 10th patient treated, the filing said.
The trial is evaluating the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer.
The medical device company's shares surged almost 8% in recent Friday trade.
Price (AUD): $0.01, Change: $+0.0010, Percent Change: +7.69%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.